(3S)-1-(3-methylpyrrolo[1,2-a]pyrazin-1-yl)pyrrolidin-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡嗪类
• 英文名称: (3S)-1-(3-methylpyrrolo[1,2-a]pyrazin-1-yl)pyrrolidin-3-amine
• 化学式: C₁₂H₁₆N₄
• 分子量: 216.28
• InChiKey: SLYDMKGQZOAEOL-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• CXCR7 ANTAGONISTS
  申请人：ChemoCentryx, Inc.

  公开号：US20140154179A1

  公开（公告）日：2014-06-05

  Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

  提供具有化学式I的化合物，或其药用可接受的盐、水合物或N-氧化物，并且这些化合物可用于与CXCR7结合，治疗部分或完全依赖于CXCR7活性的疾病。因此，根据本发明的进一步方面，提供含有上述化合物之一或多个的组合物与药用可接受的赋形剂混合物。
• CXCR7 antagonists
  申请人：CHEMOCENTRYX, INC.

  公开号：US10287292B2

  公开（公告）日：2019-05-14

  Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

  具有式 I 的化合物、 本发明提供了具有式 I 的化合物或其药学上可接受的盐、水合物或 N-氧化物，可用于与 CXCR7 结合，治疗至少部分依赖于 CXCR7 活性的疾病。因此，本发明在进一步的方面提供了含有一种或多种上述化合物与药学上可接受的赋形剂混合的组合物。
• US9169261B2
  申请人：——

  公开号：US9169261B2

  公开（公告）日：2015-10-27
• US9783544B2
  申请人：——

  公开号：US9783544B2

  公开（公告）日：2017-10-10
• [EN] CXCR7 ANTAGONISTS<br/>[FR] ANTAGONISTES DE CXCR7
  申请人：CHEMOCENTRYX INC

  公开号：WO2014085490A1

  公开（公告）日：2014-06-05

  Compounds having formula (I) (structurally represented) or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing the compounds in admixture with a pharmaceutically acceptable excipient.